International Stem Cell Corporation (ISCO) Reports Operating Results for First Quarter of 2016
Before the opening bell, International Stem Cell Corporation (OTCQB: ISCO) announced its operating results for the first quarter of 2016. The company’s consolidated revenue for the three months ended March 31 was $1.6 million, which remained unchanged from the comparable period of 2015. ISCO continued to generate revenue through its two wholly-owned subsidiaries, Lifeline Skin Care and Lifeline Cell Technology, with both remaining profitable. Profit margin for the two subsidiaries was $1.24 million, or 77 percent, for the three month period, up from $1.20 million, or 74 percent, in the previous year. “I'm happy to report that while revenues remained…